2024-11-14 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

This report analyzes AbbVie Inc. (ABBV) based on the provided data, aiming to offer insights for potential investment decisions.

**1. Performance Comparison:**

AbbVie Inc. (ABBV) is a global biopharmaceutical company that develops, manufactures, and commercializes a portfolio of medicines across various therapeutic areas.

**Cumulative Performance:**

* **ABBV:** 211.81%
* **S&P 500 (VOO):** 179.47%

**Performance Gap:**

* **Current:** 32.34%
* **Relative Gap:** 45.01% (Indicating ABBV outperformed S&P 500 by a substantial margin, currently in the top 45% of historical performance relative to S&P 500).

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 63.2% | 29.6% | 24.8% | 1.0 | 170.9 |
| 2016-2018  | 79.0% | 32.3% | 46.7% | 1.0 | 162.9 |
| 2017-2019  | 61.4% | 40.1% | 9.7% | 1.1 | 156.5 |
| 2018-2020  | 26.1% | 40.1% | -21.2% | 0.8 | 189.3 |
| 2019-2021  | 77.3% | 33.8% | -22.7% | 0.7 | 239.3 |
| 2020-2022  | 107.4% | 33.8% | 83.8% | 0.6 | 285.6 |
| 2021-2023  | 66.5% | 21.2% | 31.6% | 0.4 | 273.9 |
| 2022-2024  | 41.0% | 21.2% | 10.5% | 0.3 | 302.3 |

* **Alpha:** consistently positive, indicating ABBV consistently outperformed the market. 
* **Beta:** gradually decreasing, suggesting ABBV is becoming less volatile relative to the market.

**2. Recent Price Movements:**

* **Closing Price:** 170.35
* **5-day Moving Average:** 183.18
* **20-day Moving Average:** 191.27
* **60-day Moving Average:** 192.67

**Analysis:** ABBV is currently trading below its recent moving averages, indicating a potential short-term downtrend. However, the 60-day moving average is also decreasing, suggesting a broader bearish trend.

**3. Technical Indicators:**

* **RSI:** 32.2 - This suggests the stock is currently oversold, indicating potential rebound potential.
* **PPO:** -1.6 - This signifies a short-term negative momentum, although not significantly strong.
* **Delta_Previous_Relative_Divergence:** -29.25 (short-term bearish) - indicates potential for further price decline.
* **Expected Return:** 29.55% - This suggests a positive long-term return potential relative to the S&P 500, making ABBV an attractive candidate for a long-term investment strategy. 

**4. Recent Earnings Performance:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-30 | 3 | 2.92 |
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |

**Analysis:** ABBV has consistently exceeded earnings expectations in recent quarters. The most recent earnings report (2024-10-30) confirms this trend, with EPS exceeding the consensus estimate by a small margin. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $14.46B | 70.87% |
| 2024-06-30 | $14.46B | 70.94% |
| 2024-03-31 | $12.31B | 66.74% |
| 2023-12-31 | $14.30B | 60.11% |
| 2023-09-30 | $13.93B | 53.44% |

**Analysis:** AbbVie continues to demonstrate strong revenue growth, with significant increases in profit margins. This indicates robust profitability and efficient operations.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $6.03B | 25.88% |
| 2024-06-30 | $6.78B | 20.21% |
| 2024-03-31 | $8.01B | 17.10% |
| 2023-12-31 | $10.36B | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |

**Analysis:** The company demonstrates a strong Return on Equity (ROE), suggesting efficient utilization of capital and high profitability.  However, there is a trend of decreasing ROE, which could signal potential growth challenges in the future.

**6. News and Recent Issues:**

* **Recent Earnings News:** Refer to the recent earnings call transcripts and analyst reports (such as those from Zacks, Seeking Alpha, or MarketBeat) for details on the latest earnings release and analyst commentary.
* **Market Outlook:** Analyze recent research reports from reputable financial institutions, including FINBOLD. Look for assessments of the pharmaceutical industry,  ABBV's competitive landscape, and their future growth prospects. 
* **Analyst Opinions and Performance Highlights:** Review recent analyst ratings and target prices for ABBV, which can provide insights into their sentiment and future expectations.

**7. Comprehensive Analysis:**

* AbbVie Inc. (ABBV) has consistently outperformed the S&P 500 with a strong alpha and a gradually decreasing beta, indicating outperformance and decreasing volatility.
* The stock is currently trading below its recent moving averages, suggesting a short-term downtrend, but the 60-day moving average also shows a broader bearish trend.
* Technical indicators indicate potential for a rebound despite short-term negative momentum.
* The company demonstrates strong earnings performance with consistent exceeding of expectations and robust revenue growth.
* Financial data highlights strong profitability and efficient utilization of capital, but a slight decline in ROE might indicate potential future challenges.

**8. Recommendation:**

Despite the short-term downtrend, ABBV's long-term growth potential remains attractive. Its strong fundamentals, consistent earnings beat, and impressive historical performance make it a worthwhile consideration for investors with a long-term investment horizon. However, monitoring the company's future performance and financial health is crucial to assess any potential risks. 

**Disclaimer:** This analysis is for informational purposes only and should not be construed as investment advice. Investment decisions should be made based on your own research, financial situation, and risk tolerance. 
